Related references
Note: Only part of the references are listed.Immuno-oncological Efficacy of RXDX-106, a Novel TAM (TYRO3, AXL, MER) Family Small-Molecule Kinase Inhibitor
Yumi Yokoyama et al.
CANCER RESEARCH (2019)
Highly Selective MERTK Inhibitors Achieved by a Single Methyl Group
Jichen Zhao et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity
Alisa B. Lee-Sherick et al.
JCI INSIGHT (2018)
Discovery of Macrocyclic Pyrimidines as MerTK-Specific Inhibitors
Andrew L. McIver et al.
CHEMMEDCHEM (2017)
KinMap: a web-based tool for interactive navigation through human kinome data
Sameh Eid et al.
BMC BIOINFORMATICS (2017)
Design and Synthesis of Novel Macrocyclic Mer Tyrosine Kinase Inhibitors
Xiaodong Wang et al.
ACS MEDICINAL CHEMISTRY LETTERS (2016)
Volume of Distribution in Drug Design
Dennis A. Smith et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
UNC2025, a Potent and Orally Bioavailable MER/FLT3 Dual Inhibitor
Weihe Zhang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
The TAM family: phosphatidylserine-sensing receptor tyrosine kinases gone awry in cancer
Douglas K. Graham et al.
NATURE REVIEWS CANCER (2014)
UNC1062, a new and potent Mer inhibitor
Jing Liu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2013)
MerTK inhibition in tumor leukocytes decreases tumor growth and metastasis
Rebecca S. Cook et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
MERTK receptor tyrosine kinase is a therapeutic target in melanoma
Jennifer Schlegel et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer
R. M. A. Linger et al.
ONCOGENE (2013)
Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling
Samuel J. Taylor et al.
BLOOD (2012)
Analysis of Kinase Inhibitor Selectivity using a Thermodynamics-Based Partition Index
Alan C. Cheng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
A quantitative analysis of kinase inhibitor selectivity
Mazen W. Karaman et al.
NATURE BIOTECHNOLOGY (2008)
A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy
Steven Knapper et al.
BLOOD (2006)
Share Paper
